Mapping genetic mutations to individual cell types reveals how non-coding DNA drives complex autoimmune disease.
Most disease-associated genetic variants lie outside of genes, in the massive sequence of non-coding DNA. For decades, researchers averaged genetic signals across entire tissue samples, masking the precise cellular mechanisms that spark illness.
AlphaGenome 2 changes that spatial resolution. Trained on over 100 million single-cell profiles across 68 tissues, the model predicts how mutations alter gene expression inside specific individual cell types rather than broad tissue averages.
Precision Over Averages
By operating at single-cell resolution, the tool identifies nearly twice as many gene-expression-altering variants as its previous iteration. This enables drug discovery teams to isolate how specific non-coding mutations trigger conditions like inflammatory bowel disease and complex autoimmune disorders.
Instead of guessing which cell type drives a disease state, computational biologists can model mutation impacts in silico before entering the wet lab.
The Computational Limit
High algorithmic accuracy does not equal a validated drug target. Predictive models highlight potential disease pathways, but they do not prove therapeutic efficacy or replace experimental validation in living tissue.
Drug discovery pipelines should integrate these single-cell mutation predictions early to filter out low-probability targets, saving years of wet-lab validation while keeping physical assays focused on high-confidence cellular candidates.
